ID

38157

Beschrijving

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01872260

Link

https://clinicaltrials.gov/show/NCT01872260

Trefwoorden

Versies (1)
  1. 23-09-19 23-09-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

23 september 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Breast Cancer NCT01872260

Engels

Eligibility Breast Cancer NCT01872260

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal, estrogen-receptor positive breast cancer
Beschrijving

Postmenopausal state | Oestrogen receptor positive breast cancer

Datatype

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C2938924
phase ib dose escalation only: any number of prior lines of endocrine therapy is allowed with the exception of cytotoxic therapy which is limited to one prior line administered in the advanced (metastatic or locally advanced) setting.
Beschrijving

Dose Escalation | Hormone Therapy Quantity | Cytotoxic Chemotherapy Neoplasm Metastasis Advanced | Cytotoxic Chemotherapy Locally Advanced Disease Setting

Datatype

boolean

Alias
UMLS CUI [1]
C3816728
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1265611
UMLS CUI [3,1]
C0677881
UMLS CUI [3,2]
C0027627
UMLS CUI [3,3]
C0205179
UMLS CUI [4,1]
C0677881
UMLS CUI [4,2]
C4086552
phase ib dose expansions: no prior systemic treatment in the advanced (metastatic or locally advanced) setting with the exception of treatment with letrozole for a maximum of one month prior to starting study treatment.
Beschrijving

Dose Expansion | Systemic therapy Absent | Neoplasm Metastasis Advanced | Locally Advanced Disease Setting | Exception Letrozole

Datatype

boolean

Alias
UMLS CUI [1]
C4521283
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0027627
UMLS CUI [3,2]
C0205179
UMLS CUI [4]
C4086552
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0246421
phase ii: no prior systemic treatment in the advanced (metastatic or locally advanced) setting.
Beschrijving

Systemic therapy Absent | Neoplasm Metastasis Advanced | Locally Advanced Disease Setting

Datatype

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0205179
UMLS CUI [3]
C4086552
phase ib dose expansions and phase ii: patients who received (neo)adjuvant therapy for breast cancer are eligible. prior therapy with letrozole or anastrozole in the (neo)adjuvant setting is permitted if the disease free interval is greater than 12 months from the completion of treatment.
Beschrijving

Dose Expansion | Neoadjuvant Therapy Breast Carcinoma | Adjuvant therapy Breast Carcinoma | letrozole | anastrozole | Interval Disease Free

Datatype

boolean

Alias
UMLS CUI [1]
C4521283
UMLS CUI [2,1]
C0600558
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C0677850
UMLS CUI [3,2]
C0678222
UMLS CUI [4]
C0246421
UMLS CUI [5]
C0290883
UMLS CUI [6,1]
C1272706
UMLS CUI [6,2]
C0012634
UMLS CUI [6,3]
C0332296
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
her2-overexpression in the patient's tumor tissue
Beschrijving

Tumor tissue sample HER2 Protein Overexpression

Datatype

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C1515560
patients with active cns or other brain metastases
Beschrijving

CNS metastases | Metastatic malignant neoplasm to brain

Datatype

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C0220650
major surgery within 2 weeks
Beschrijving

Major surgery

Datatype

boolean

Alias
UMLS CUI [1]
C0679637
acute or chronic pancreatitis
Beschrijving

Pancreatitis | Pancreatitis, Chronic

Datatype

boolean

Alias
UMLS CUI [1]
C0030305
UMLS CUI [2]
C0149521
bilateral diffuse lymphangitic carcinomatosis
Beschrijving

Lymphangitis carcinomatosa Diffuse Bilateral

Datatype

boolean

Alias
UMLS CUI [1,1]
C0238258
UMLS CUI [1,2]
C0205219
UMLS CUI [1,3]
C0238767
another malignancy within 3 years
Beschrijving

Cancer Other

Datatype

boolean

Alias
UMLS CUI [1]
C1707251
receiving hormone replacement therapy that cannot be discontinued
Beschrijving

Hormone replacement therapy Discontinuation Unsuccessful

Datatype

boolean

Alias
UMLS CUI [1,1]
C0282402
UMLS CUI [1,2]
C1444662
UMLS CUI [1,3]
C1272705
impaired cardiac function
Beschrijving

Decreased cardiac function

Datatype

boolean

Alias
UMLS CUI [1]
C0232166
patients with clinically manifest diabetes mellitus (treated and/or clinical signs or with fasting glucose ≥ 126 mg/dl / 7.0 mmol/l or hemoglobin a1c >6.5%), history of gestational diabetes mellitus or documented steroid-induced diabetes mellitus.
Beschrijving

Diabetes Mellitus Treated | Sign or Symptom Diabetes Mellitus | Glucose measurement, fasting | Hemoglobin A1c measurement | Gestational Diabetes | Steroid-induced diabetes

Datatype

boolean

Alias
UMLS CUI [1,1]
C0011849
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C3540840
UMLS CUI [2,2]
C0011849
UMLS CUI [3]
C0202045
UMLS CUI [4]
C0474680
UMLS CUI [5]
C0085207
UMLS CUI [6]
C0342269
other protocol-defined inclusion/exclusion criteria may apply
Beschrijving

Clinical Trial Eligibility Criteria Study Protocol

Datatype

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Terug naar het begin van de pagina

Similar models

Eligibility Breast Cancer NCT01872260

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state | Oestrogen receptor positive breast cancer
Item
postmenopausal, estrogen-receptor positive breast cancer
boolean
C0232970 (UMLS CUI [1])
C2938924 (UMLS CUI [2])
Dose Escalation | Hormone Therapy Quantity | Cytotoxic Chemotherapy Neoplasm Metastasis Advanced | Cytotoxic Chemotherapy Locally Advanced Disease Setting
Item
phase ib dose escalation only: any number of prior lines of endocrine therapy is allowed with the exception of cytotoxic therapy which is limited to one prior line administered in the advanced (metastatic or locally advanced) setting.
boolean
C3816728 (UMLS CUI [1])
C0279025 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0677881 (UMLS CUI [3,1])
C0027627 (UMLS CUI [3,2])
C0205179 (UMLS CUI [3,3])
C0677881 (UMLS CUI [4,1])
C4086552 (UMLS CUI [4,2])
Dose Expansion | Systemic therapy Absent | Neoplasm Metastasis Advanced | Locally Advanced Disease Setting | Exception Letrozole
Item
phase ib dose expansions: no prior systemic treatment in the advanced (metastatic or locally advanced) setting with the exception of treatment with letrozole for a maximum of one month prior to starting study treatment.
boolean
C4521283 (UMLS CUI [1])
C1515119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0027627 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C4086552 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C0246421 (UMLS CUI [5,2])
Systemic therapy Absent | Neoplasm Metastasis Advanced | Locally Advanced Disease Setting
Item
phase ii: no prior systemic treatment in the advanced (metastatic or locally advanced) setting.
boolean
C1515119 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C4086552 (UMLS CUI [3])
Dose Expansion | Neoadjuvant Therapy Breast Carcinoma | Adjuvant therapy Breast Carcinoma | letrozole | anastrozole | Interval Disease Free
Item
phase ib dose expansions and phase ii: patients who received (neo)adjuvant therapy for breast cancer are eligible. prior therapy with letrozole or anastrozole in the (neo)adjuvant setting is permitted if the disease free interval is greater than 12 months from the completion of treatment.
boolean
C4521283 (UMLS CUI [1])
C0600558 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C0677850 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
C0246421 (UMLS CUI [4])
C0290883 (UMLS CUI [5])
C1272706 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
Item Group
C0680251 (UMLS CUI)
Tumor tissue sample HER2 Protein Overexpression
Item
her2-overexpression in the patient's tumor tissue
boolean
C0475358 (UMLS CUI [1,1])
C1515560 (UMLS CUI [1,2])
CNS metastases | Metastatic malignant neoplasm to brain
Item
patients with active cns or other brain metastases
boolean
C0686377 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
Major surgery
Item
major surgery within 2 weeks
boolean
C0679637 (UMLS CUI [1])
Pancreatitis | Pancreatitis, Chronic
Item
acute or chronic pancreatitis
boolean
C0030305 (UMLS CUI [1])
C0149521 (UMLS CUI [2])
Lymphangitis carcinomatosa Diffuse Bilateral
Item
bilateral diffuse lymphangitic carcinomatosis
boolean
C0238258 (UMLS CUI [1,1])
C0205219 (UMLS CUI [1,2])
C0238767 (UMLS CUI [1,3])
Cancer Other
Item
another malignancy within 3 years
boolean
C1707251 (UMLS CUI [1])
Hormone replacement therapy Discontinuation Unsuccessful
Item
receiving hormone replacement therapy that cannot be discontinued
boolean
C0282402 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C1272705 (UMLS CUI [1,3])
Decreased cardiac function
Item
impaired cardiac function
boolean
C0232166 (UMLS CUI [1])
Diabetes Mellitus Treated | Sign or Symptom Diabetes Mellitus | Glucose measurement, fasting | Hemoglobin A1c measurement | Gestational Diabetes | Steroid-induced diabetes
Item
patients with clinically manifest diabetes mellitus (treated and/or clinical signs or with fasting glucose ≥ 126 mg/dl / 7.0 mmol/l or hemoglobin a1c >6.5%), history of gestational diabetes mellitus or documented steroid-induced diabetes mellitus.
boolean
C0011849 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C3540840 (UMLS CUI [2,1])
C0011849 (UMLS CUI [2,2])
C0202045 (UMLS CUI [3])
C0474680 (UMLS CUI [4])
C0085207 (UMLS CUI [5])
C0342269 (UMLS CUI [6])
Clinical Trial Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial